NYSEARCA:MAIA - NYSE Arca - US5526411021 - Common Stock - Currency: USD
1.65
-0.07 (-4.07%)
The current stock price of MAIA is 1.65 USD. In the past month the price decreased by -8.33%. In the past year, price decreased by -44.07%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.62 | 337.77B | ||
AMGN | AMGEN INC | 14.62 | 163.23B | ||
GILD | GILEAD SCIENCES INC | 14.76 | 142.09B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.29B | ||
REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.26B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.10B | ||
ARGX | ARGENX SE - ADR | 104.32 | 36.65B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.82 | 33.09B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.80B | ||
INSM | INSMED INC | N/A | 19.92B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.86B | ||
BIIB | BIOGEN INC | 8.08 | 18.74B |
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
MAIA BIOTECHNOLOGY INC
444 West Lake Street, Suite 1700, Suite 1700
Chicago ILLINOIS US
Employees: 13
Phone: 13124168592
The current stock price of MAIA is 1.65 USD. The price decreased by -4.07% in the last trading session.
The exchange symbol of MAIA BIOTECHNOLOGY INC is MAIA and it is listed on the NYSE Arca exchange.
MAIA stock is listed on the NYSE Arca exchange.
7 analysts have analysed MAIA and the average price target is 14.28 USD. This implies a price increase of 765.45% is expected in the next year compared to the current price of 1.65. Check the MAIA BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MAIA BIOTECHNOLOGY INC (MAIA) has a market capitalization of 50.01M USD. This makes MAIA a Micro Cap stock.
MAIA BIOTECHNOLOGY INC (MAIA) currently has 13 employees.
MAIA BIOTECHNOLOGY INC (MAIA) has a support level at 1.65 and a resistance level at 1.71. Check the full technical report for a detailed analysis of MAIA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MAIA does not pay a dividend.
MAIA BIOTECHNOLOGY INC (MAIA) will report earnings on 2025-08-08.
MAIA BIOTECHNOLOGY INC (MAIA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
The outstanding short interest for MAIA BIOTECHNOLOGY INC (MAIA) is 1.75% of its float. Check the ownership tab for more information on the MAIA short interest.
ChartMill assigns a fundamental rating of 2 / 10 to MAIA. MAIA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months MAIA reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 49.68% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -166.08% | ||
ROE | -398.67% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to MAIA. The Buy consensus is the average rating of analysts ratings from 7 analysts.